Information Provided By: 
Fly News Breaks for April 13, 2017
BVX
Apr 13, 2017 | 04:24 EDT
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien says Bovie Medical's growth is being underappreciated by investors. The company's J-Plasma technology has the potential to drive "considerable growth" over the next several years, O'Brien tells investors in a research note. He believes "patient investors" should be starting positions at current share levels. The analyst has an Overweight rating on Bovie with a $6 price target.
News For BVX From the Last 2 Days
There are no results for your query BVX
